Cargando…

Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment

The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Casaburi, Ivan, Chimento, Adele, De Luca, Arianna, Nocito, Marta, Sculco, Sara, Avena, Paola, Trotta, Francesca, Rago, Vittoria, Sirianni, Rosa, Pezzi, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141749/
https://www.ncbi.nlm.nih.gov/pubmed/30254608
http://dx.doi.org/10.3389/fendo.2018.00525
_version_ 1783355763698171904
author Casaburi, Ivan
Chimento, Adele
De Luca, Arianna
Nocito, Marta
Sculco, Sara
Avena, Paola
Trotta, Francesca
Rago, Vittoria
Sirianni, Rosa
Pezzi, Vincenzo
author_facet Casaburi, Ivan
Chimento, Adele
De Luca, Arianna
Nocito, Marta
Sculco, Sara
Avena, Paola
Trotta, Francesca
Rago, Vittoria
Sirianni, Rosa
Pezzi, Vincenzo
author_sort Casaburi, Ivan
collection PubMed
description The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased.
format Online
Article
Text
id pubmed-6141749
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61417492018-09-25 Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment Casaburi, Ivan Chimento, Adele De Luca, Arianna Nocito, Marta Sculco, Sara Avena, Paola Trotta, Francesca Rago, Vittoria Sirianni, Rosa Pezzi, Vincenzo Front Endocrinol (Lausanne) Endocrinology The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased. Frontiers Media S.A. 2018-09-11 /pmc/articles/PMC6141749/ /pubmed/30254608 http://dx.doi.org/10.3389/fendo.2018.00525 Text en Copyright © 2018 Casaburi, Chimento, De Luca, Nocito, Sculco, Avena, Trotta, Rago, Sirianni and Pezzi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Casaburi, Ivan
Chimento, Adele
De Luca, Arianna
Nocito, Marta
Sculco, Sara
Avena, Paola
Trotta, Francesca
Rago, Vittoria
Sirianni, Rosa
Pezzi, Vincenzo
Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title_full Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title_fullStr Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title_full_unstemmed Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title_short Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
title_sort cholesterol as an endogenous errα agonist: a new perspective to cancer treatment
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141749/
https://www.ncbi.nlm.nih.gov/pubmed/30254608
http://dx.doi.org/10.3389/fendo.2018.00525
work_keys_str_mv AT casaburiivan cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT chimentoadele cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT delucaarianna cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT nocitomarta cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT sculcosara cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT avenapaola cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT trottafrancesca cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT ragovittoria cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT siriannirosa cholesterolasanendogenouserraagonistanewperspectivetocancertreatment
AT pezzivincenzo cholesterolasanendogenouserraagonistanewperspectivetocancertreatment